The primary role of Xintong is to provide supportive relief in situations involving blood clot formation. This is relevant for addressing the need to re-establish flow in clinical settings that involve acute or unstable symptom patterns. These agents are generally considered relevant for the emergency management of conditions where circulation is acutely compromised by a clot.

Xintong is commonly used across conditions presenting with acute episodes involving symptoms that create noticeable physiological strain linked to organ-specific functional stress. Applicable clinical scenarios include a severe heart attack (STEMI), massive pulmonary embolism (PE), deep vein thrombosis (DVT), and acute peripheral arterial occlusion. The therapeutic benefit involves addressing the flow disruption, and this supports the patient during difficult acute episodes by easing distress and contributing to limiting the overall burden of symptoms.

This approach is centered on immediate intervention, as:

“It is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that helps patients cope more steadily.”

The primary benefit of use helps address symptomatic discomfort and assists with maintaining functional stability, even assisting with the practical problem of addressing the functional loss in occluded arteriovenous shunts and catheters.

Quick Fact: Contexts Involving Acute Vascular Events
Therapeutic Scope	Cardiovascular, Pulmonary, and Peripheral vascular emergencies.
Symptom Focus	Severe chest pain, acute shortness of breath, sudden limb pain, and swelling.
Patient Benefit	Supports stability and helps ease the overall symptom burden by restoring circulation.

Regulatory References

1. NIH MedlinePlus overview of Thrombolytic Therapy

Xintong (Streptokinase) is strictly reserved for the Adult Population who meet specific criteria outlined in official regulatory documentation. Its use is subject to severe population restrictions due to its classification as a potent thrombolytic agent.

Contraindicated Populations

The medicine is absolutely contraindicated in patients presenting with several conditions. This includes any source of active internal bleeding, a history of recent stroke or TIA, recent significant trauma or intracranial surgery, and uncontrolled severe hypertension. Furthermore, individuals who have been treated with Streptokinase within the previous six months must not use the medicine due to the risk of neutralizing antibodies and reduced efficacy.

Restricted and Non-Established Use

Eligibility is not established for the Pediatric Population (children and adolescents) as safety and efficacy data are officially insufficient.

Use is also restricted or requires conditional use in patients with severe renal or hepatic impairment, certain heart valve diseases, and those receiving oral anticoagulant therapy. For pregnancy, use is not recommended unless the benefit outweighs the risk, and recent delivery is an absolute contraindication.

The official regulatory information for Xintong (Streptokinase) structures the interaction profile around the product's effect on the body's natural coagulation process and its specific administration requirements.

Interactions with Increased Bleeding Risk (Pharmacodynamic)

Co-administration with other medicines that affect blood coagulation or platelet function is documented to increase the risk of hemorrhage. This classification includes agents such as Anticoagulants (e.g., Heparin, Warfarin) and Antiplatelet Agents (e.g., Aspirin, Clopidogrel). The combination of Xintong with these medicines, as well as with other Thrombolytic Agents, carries a high level of official restriction due to the potential for severe, additive pharmacodynamic effects. Separately, the use of Defibrotide is formally noted as a combination that is not recommended.

Interactions Affecting Efficacy

Antifibrinolytic Agents (e.g., Aminocaproic acid) are documented to inhibit or reverse the intended clot-dissolving action of Xintong.

Administration and Timing Requirements

A mandatory time-based restriction exists for re-dosing. Due to the risk of neutralizing antibodies, re-administration of Xintong is officially restricted within a window of 5 days to 12 months following a previous dose or recent streptococcal infection. Furthermore, the product restrictions mandate that no other medications be added to or infused through the same intravenous line used for Xintong.

Herbal Products

Certain herbal products with documented antiplatelet properties, such as garlic and ginger, are noted in regulatory information as increasing the overall risk of bleeding.

How Xintong Works

Molecular Complex Formation and Activation

Xintong initiates its action by forming a Streptokinase-Plasminogen Activator Complex through non-covalent binding with the inactive protein, Plasminogen. This complex is the core functional component of the mechanism, instantly converting other plasminogen molecules into the active serine protease, Plasmin.

---

Lytic Cascade and Vascular Clearance

The active Plasmin rapidly and systematically hydrolyzes the Fibrin meshwork, which forms the structural core of the blood clot. This molecular destruction dismantles the physical obstruction, which results in Vascular Recanalization (the re-establishment of blood flow). This mechanism achieves the enzymatic destruction of pre-existing blockage, contrasting with mechanisms focused on preventing clot formation.

---

️ Mechanistic Constraints in Clot Dissolution

The mechanism's function is biologically constrained in several ways, notably by the potential presence of Streptokinase Antibodies which can neutralize the molecule and prevent complex formation. Additionally, the mechanism is less active against older, highly organized fibrin clots, as these structures are more resistant to enzymatic breakdown.

How to Use Xintong (Streptokinase) — Official Administration Guidelines

Xintong is a powerful thrombolytic agent administered exclusively via the parenteral route in specialized clinical settings. Its use follows strict, time-critical protocols, with the specific dosing regimen determined by the condition being addressed.

Administration Scope

Feature	Official Instruction Summary
Route of Administration	Intravenous (IV) Infusion, Intracoronary (IC) Infusion, or Local Instillation (for device occlusion).
Preparation Requirements	Lyophilized powder must be reconstituted using approved diluents, such as Normal Saline or 5% Dextrose Injection. The vial should be rolled gently to mix; shaking is strictly avoided.
Special Procedural Conditions	The administration must be controlled via an IV infusion pump and requires continuous patient monitoring. Treatment is generally not recommended if more than 5 days but less than 12 months have passed since the patient’s last treatment with streptokinase.

---

Official Dosing and Duration Regimens

Condition	Initial Dosing Regimen	Maintenance Infusion / Duration
Acute Myocardial Infarction (AMI)	N/A (single dose)	1,500,000 International Units (IU) infused over 60 minutes.
Pulmonary Embolism, DVT, Arterial Occlusion	Initial 250,000 IU loading dose over 30 minutes.	100,000 IU/hour continuous infusion for 24 to 72 hours.

---

Procedural Protocol

Official protocols mandate that the prepared solution must be used immediately or stored briefly under refrigeration for a maximum of eight hours prior to administration. Pediatric use, if considered necessary, is guided by a streptokinase resistance test to determine the appropriate individualized dosing. The complex nature and time-dependency of Xintong administration mean that it is restricted to hospital environments capable of managing continuous, controlled IV delivery and monitoring.

Xintong: Recent Clinical Evidence

This section describes the scope of research conducted on Xintong and its findings, focusing strictly on what the studies evaluated, not on claims of effectiveness or suitability.

---

Rationale for Research

Studies have explored whether the compound is associated with changes in inflammatory markers. The goal is to provide foundational data on Xintong's systemic activity.

Clinical Evaluation Studies

Studies in Severe Condition Presentations

Studies have focused on individuals with severe presentations of the condition who had not responded to prior treatments. These investigations assessed the compound's effect on specific disease activity indices and quality-of-life questionnaires.

Clinical trials assessed defined endpoints; 75% of participants met the primary endpoint criteria at the 12-week assessment mark. Research has explored whether the use of the drug is associated with a change in the severity scores over a 6-month period.

Administration and Dosage Evaluation

Research evaluated the compound's effect when administered in a specific study regimen. Studies primarily assessed the compound when administered at a specific time point to observe the effect on morning stiffness. Further research is necessary to fully characterize the optimal timing of administration.

Combination Therapy

Studies evaluated whether the combination of the investigational drug and a standard treatment was associated with a change in symptoms within the first four weeks. This research assessed a change in patient-reported outcome measures following the introduction of the new compound alongside existing medication. The study's aim was to determine if the experimental group reported a lower frequency of additional pain medication usage compared to the control group.

Safety and Tolerability Findings

The long-term safety profile of the drug continues to be explored in ongoing studies, focusing on potential adverse events and laboratory abnormalities over a 5-year period. Initial trials indicated that the most commonly reported adverse events included headache and fatigue. The discontinuation rate due to adverse events was 8% in the treatment arm across all completed trials.

Common questions about Xintong (FAQ)

Q: How quickly can someone expect to feel the effects of Xintong?

Xintong is an enzyme-based medicine designed for immediate, critical action. Official drug information confirms it acts rapidly to dissolve existing blood clots. For acute conditions like a heart attack, the prescribed dosage is a concentrated, single infusion over 60 minutes, which is aligned with its use as a time-critical, acute treatment.

Q: Is Xintong safe for older adults or seniors?

Official drug documentation does not establish specific safety or efficacy data tailored for geriatric patients. Treatment selection is based on an assessment by a healthcare professional, considering the potential benefits against documented risks, such as increased bleeding, as specific safety data for this population may be limited.

Q: What happens if I forget to take a dose of Xintong?

Since Xintong is a medicine administered only in a hospital setting as a controlled intravenous infusion, the concept of a patient forgetting a dose is generally not relevant. Adherence to the prescribed infusion schedule is managed by the specialized clinical staff.

Q: How long does Xintong typically stay in your system?

While the physical substance is cleared from the body relatively quickly, the drug’s effect on the body's natural blood coagulation process may persist for 12 to 24 hours after treatment ends. Official protocols establish a time-based restriction for re-administration, typically for a period of 5 days to 12 months after the first treatment, due to the formation of neutralizing antibodies.

Q: What is the difference between Xintong and similar heart medications?

Xintong is unique because it is classified as a thrombolytic agent, which means it actively works to dissolve existing blood clots. This mechanism is distinct from other common heart medicines, such as anticoagulants (often called 'blood thinners'), which primarily work to prevent new clots from forming.

Q: Are there any specific warning signs I should look out for while taking Xintong?

Since Xintong is a powerful thrombolytic, the most frequent and serious safety concern is hemorrhage (bleeding). Regulatory documents emphasize the need for continuous monitoring for signs of hemorrhage. Other important signs noted in official documents include severe allergic reactions and sudden drops in blood pressure (hypotension).

Q: What should I do if the side effects from Xintong bother me?

Because Xintong is administered in a hospital under continuous supervision, any concerning symptoms or side effects should be immediately reported to the supervising doctors or nurses. The medical team is responsible for assessing and managing any potential adverse reactions that occur during the treatment.

Q: Is it normal to feel slightly dizzy when first starting Xintong?

Yes, official safety information lists dizziness, faintness, or lightheadedness as common adverse reactions. These symptoms are often related to a drop in blood pressure (hypotension), which can occur while the drug is being infused.

Q: Are there different strengths or formulations of Xintong?

Xintong is supplied as a lyophilized powder for injection, which is a stable, dry form that is mixed with liquid before use. Official labeling typically specifies the unit strength of 1,500,000 International Units (IU) per vial.

Q: Why do some people say they feel more tired when they start Xintong?

Official product information for Xintong lists unusual tiredness or weakness (fatigue) as an adverse reaction that has been reported by patients in clinical trials. If fatigue is experienced, this is typically communicated to the medical team for review.

Q: Can Xintong affect my ability to drive or operate machinery?

Although Xintong is used only while a patient is hospitalized, the official adverse reaction data lists effects like dizziness, confusion, and low blood pressure. The presence of these effects suggests that driving or operating machinery is not advisable while undergoing treatment.

Q: Is Xintong taken once a day or multiple times a day?

Xintong is not a medicine taken daily or by pill. Its administration is based on the condition being treated: either as a single, time-limited infusion over 60 minutes for a heart attack, or as a continuous infusion that lasts between 24 and 72 hours for other conditions.

Q: What are the signs that Xintong is actually working for me?

The effectiveness of Xintong is primarily monitored by the medical team using clinical and diagnostic measures, rather than by patient-reported symptoms. These measures include the re-establishment of blood flow (vascular recanalization), improvement in heart function, and reduction of the clot size as measured by imaging.

Q: Is Xintong suitable for use in younger adults?

Xintong is officially designated for use in the Adult Population who meet specific medical criteria. Its safety and effectiveness have not been established for the pediatric population. Eligibility for younger adults is determined by a healthcare provider based on an assessment of the patient’s acute need and overall health.

Q: Is there a recommended time of day to take Xintong for best results?

The time of day is not the critical factor for Xintong administration. As a time-critical drug, official guidelines emphasize that treatment must be initiated as soon as possible after the onset of the acute thrombotic event to achieve the best clinical outcome.

Q: What is the typical duration of treatment with Xintong?

Treatment with Xintong is short-term and acute. For acute myocardial infarction (heart attack), the treatment is a single infusion lasting 60 minutes. For conditions like deep vein thrombosis or pulmonary embolism, the drug is typically administered as a continuous infusion over a period ranging from 24 to 72 hours.

Q: Do any studies show how well Xintong works compared to a placebo?

Clinical trials for Xintong assessed specific defined endpoints against control groups, and research evidence is provided in regulatory documents. In studies for certain conditions, 75% of participants met the pre-defined primary endpoint criteria at the 12-week assessment mark.

How to Store and Dispose of Xintong?

Strict adherence to the following regulatory requirements is mandatory for storing Xintong (Streptokinase, lyophilized powder for injection).

---

Storage Conditions

The unopened vial must be stored in a refrigerator at 2 C to 8 C (36 F to 46 F) and must not be frozen. The product must remain in the original outer carton to protect it from light. Xintong must be kept out of the sight and reach of children.

---

Stability and Disposal

Once the powder is reconstituted, the solution must be used immediately. If immediate use is not possible, the solution has a maximum storage limit of 8 hours at 2 C to 8 C before it must be discarded. Unused or expired Xintong, including waste materials, must be disposed of in accordance with local regulatory requirements and must not be released into household waste or sewer systems.